Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Systemic therapy in resectable breast cancer.

G Bonadonna1, P Valagussa

  • 1Istituto Nazionale Tumori, Milan, Italy.

Hematology/Oncology Clinics of North America
|December 1, 1989
PubMed
Summary

Adjuvant systemic therapy for high-risk breast cancer significantly reduces mortality. While benefits are moderate, chemotherapy and hormonal therapy offer clinically important improvements for node-positive and node-negative tumors.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Response of diademed sifaka (<i>Propithecus diadema</i>) to fosa (<i>Cryptoprocta ferox</i>) predation in the Betampona Strict Nature Reserve, Madagascar.

Ecology and evolution·2024
Same author

Degenerative and inflammatory musculoskeletal disorders: updates and hot topics in diagnostic and interventional imaging.

European review for medical and pharmacological sciences·2022
Same author

Second malignancy risk associated with treatment of Hodgkin's lymphoma: meta-analysis of the randomised trials.

Annals of oncology : official journal of the European Society for Medical Oncology·2006
Same author

Breast cancer recurrence dynamics following adjuvant CMF is consistent with tumor dormancy and mastectomy-driven acceleration of the metastatic process.

Annals of oncology : official journal of the European Society for Medical Oncology·2005
Same author

Primary chemotherapy followed by anterior craniofacial resection and radiotherapy for paranasal cancer.

Annals of oncology : official journal of the European Society for Medical Oncology·2003
Same author

Double-peaked time distribution of mortality for breast cancer patients undergoing mastectomy.

Breast cancer research and treatment·2002

Area of Science:

  • Oncology
  • Medical Oncology
  • Breast Cancer Research

Background:

  • Adjuvant systemic therapy plays a crucial role in managing high-risk breast cancer.
  • Evidence supports a moderate yet clinically significant reduction in tumor mortality at 5 years.
  • Treatment decisions involve chemotherapy and hormonal therapy, with specific considerations for tumor characteristics.

Purpose of the Study:

  • To review the evidence for adjuvant systemic therapy in high-risk breast cancer.
  • To discuss common chemotherapy and hormonal therapy regimens.
  • To explore the role of neoadjuvant chemotherapy and monitor long-term toxicity.

Main Methods:

  • Review of existing evidence on adjuvant systemic therapy efficacy.
  • Discussion of current chemotherapy and hormonal therapy options.
  • Evaluation of preliminary data on neoadjuvant chemotherapy.

Main Results:

  • Convincing evidence shows adjuvant systemic therapy reduces 5-year tumor mortality in high-risk breast cancer.
  • Moderate but clinically important treatment benefits are observed, particularly for node-positive tumors.
  • Preliminary evidence suggests benefit from adjuvant combination chemotherapy for node-negative, receptor-negative tumors.

Conclusions:

  • Adjuvant systemic therapy is a valuable component in treating high-risk breast cancer.
  • Chemotherapy and hormonal therapy are key treatment modalities.
  • Neoadjuvant chemotherapy shows promise for enabling conservative surgery but requires further study; long-term toxicity monitoring is essential.

Related Experiment Videos